Induction Therapy in Localized Pancreatic Cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Localized pancreatic cancer (PDAC) presents in resectable (RPC), borderline resectable (BRPC), and locally advanced unresectable (LAPC) stages.
• Adjuvant chemotherapy is standard for RPC; optimal treatment for BRPC and LAPC remains under investigation.
• Induction chemotherapy is increasingly explored for localized PDAC to improve resectability and outcomes.

Purpose of the Study:

• To evaluate the impact of induction chemotherapy on overall survival (OS) in localized pancreatic cancer (PDAC).
• To compare outcomes between different stages of localized PDAC (RPC, BRPC, LAPC) treated with varying chemotherapy regimens.
• To assess the role of neoadjuvant therapy in optimizing treatment strategies for localized PDAC.

Main Methods:

• Retrospective review of 409 localized PDAC patients treated between 2009 and 2016.
• Patient data included demographics, tumor stage (RPC, BRPC, LAPC), chemotherapy type, and surgical status.
• Overall survival (OS) was the primary endpoint, with resectability determined by a multidisciplinary tumor conference.

Main Results:

• Median OS for RPC, BRPC, and LAPC were 19.5, 16.1, and 12.7 months, respectively.
• Patients with BRPC receiving induction chemotherapy followed by resection had a median OS of 31.5 months, significantly better than RPC patients (19.5 months).
• Chemotherapy type and patient age were significant predictors of OS.

Conclusions:

• Induction chemotherapy followed by resection significantly improves OS in borderline resectable pancreatic cancer (BRPC) compared to resectable pancreatic cancer (RPC).
• Neoadjuvant treatment strategies should be strongly considered for all stages of localized pancreatic cancer (PDAC).
• Further research into neoadjuvant therapies is crucial for optimizing pancreatic cancer treatment paradigms.